201 related articles for article (PubMed ID: 19553113)
1. Dopamine D(3) receptor antagonists: The quest for a potentially selective PET ligand. Part two: Lead optimization.
Micheli F; Holmes I; Arista L; Bonanomi G; Braggio S; Cardullo F; Di Fabio R; Donati D; Gentile G; Hamprecht D; Terreni S; Heidbreder C; Savoia C; Griffante C; Worby A
Bioorg Med Chem Lett; 2009 Aug; 19(15):4011-3. PubMed ID: 19553113
[TBL] [Abstract][Full Text] [Related]
2. Dopamine D3 receptor antagonists: the quest for a potentially selective PET ligand. Part one: lead identification.
Holmes IP; Micheli F; Gaines S; Lorthioir O; Watson SP; Fabio RD; Gentile G; Heidbreder C; Savoia C; Worby A
Bioorg Med Chem Lett; 2009 Aug; 19(16):4799-801. PubMed ID: 19560918
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D3 receptor antagonists: the quest for a potentially selective PET ligand. Part 3: Radiosynthesis and in vivo studies.
Bennacef I; Salinas CA; Bonasera TA; Gunn RN; Audrain H; Jakobsen S; Nabulsi N; Weinzimmer D; Carson RE; Huang Y; Holmes I; Micheli F; Heidbreder C; Gentile G; Rossi T; Laruelle M
Bioorg Med Chem Lett; 2009 Sep; 19(17):5056-9. PubMed ID: 19635669
[TBL] [Abstract][Full Text] [Related]
4. Structure-selectivity investigations of D2-like receptor ligands by CoMFA and CoMSIA guiding the discovery of D3 selective PET radioligands.
Salama I; Hocke C; Utz W; Prante O; Boeckler F; Hübner H; Kuwert T; Gmeiner P
J Med Chem; 2007 Feb; 50(3):489-500. PubMed ID: 17266201
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D3 receptor ligands with antagonist properties.
Hackling AE; Stark H
Chembiochem; 2002 Oct; 3(10):946-61. PubMed ID: 12362359
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and evaluation of hexahydrobenz[f]isoquinolines as a novel class of dopamine 3 receptor ligands.
Wu X; Chen J; Ji M; Varady J; Levant B; Wang S
Bioorg Med Chem Lett; 2004 Dec; 14(23):5813-6. PubMed ID: 15501046
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and structure-activity relationship studies of hexahydropyrazinoquinolines as a novel class of potent and selective dopamine receptor 3 (D3) ligands.
Ji M; Chen J; Ding K; Wu X; Varady J; Levant B; Wang S
Bioorg Med Chem Lett; 2005 Mar; 15(6):1701-5. PubMed ID: 15745825
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands for visualization of brain dopamine D3 receptors.
Leopoldo M; Lacivita E; De Giorgio P; Colabufo NA; Niso M; Berardi F; Perrone R
J Med Chem; 2006 Jan; 49(1):358-65. PubMed ID: 16392820
[TBL] [Abstract][Full Text] [Related]
9. Side effects profile in humans of (11)C-(+)-PHNO, a dopamine D(2/3) agonist ligand for PET.
Mizrahi R; Houle S; Vitcu I; Ng A; Wilson AA
J Nucl Med; 2010 Mar; 51(3):496-7. PubMed ID: 20150251
[No Abstract] [Full Text] [Related]
10. Synthesis, binding affinity and SAR of new benzolactam derivatives as dopamine D3 receptor ligands.
Ortega R; Raviña E; Masaguer CF; Areias F; Brea J; Loza MI; López L; Selent J; Pastor M; Sanz F
Bioorg Med Chem Lett; 2009 Mar; 19(6):1773-8. PubMed ID: 19217777
[TBL] [Abstract][Full Text] [Related]
11. Markers of D(2) and D(3) receptor activity in vivo: PET scan and prolactin.
Thomasson-Perret N; Pénélaud PF; Théron D; Gouttefangeas S; Mocaër E
Therapie; 2008; 63(3):237-42. PubMed ID: 18718212
[TBL] [Abstract][Full Text] [Related]
12. Hybrid approach for the design of highly affine and selective dopamine D(3) receptor ligands using privileged scaffolds of biogenic amine GPCR ligands.
Sasse BC; Mach UR; Leppaenen J; Calmels T; Stark H
Bioorg Med Chem; 2007 Dec; 15(23):7258-73. PubMed ID: 17826096
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands with optimal lipophilicity for brain imaging of the dopamine D3 receptor. Part II.
Leopoldo M; Lacivita E; De Giorgio P; Contino M; Berardi F; Perrone R
Bioorg Med Chem; 2009 Jan; 17(2):758-66. PubMed ID: 19081257
[TBL] [Abstract][Full Text] [Related]
14. Enantiomerically pure hexahydropyrazinoquinolines as potent and selective dopamine 3 subtype receptor ligands.
Ding K; Chen J; Ji M; Wu X; Varady J; Yang CY; Lu Y; Deschamps JR; Levant B; Wang S
J Med Chem; 2005 May; 48(9):3171-81. PubMed ID: 15857123
[TBL] [Abstract][Full Text] [Related]
15. New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.
Micheli F; Bonanomi G; Braggio S; Capelli AM; Damiani F; Di Fabio R; Donati D; Gentile G; Hamprecht D; Perini O; Petrone M; Tedesco G; Terreni S; Worby A; Heidbreder C
Bioorg Med Chem Lett; 2008 Feb; 18(3):908-12. PubMed ID: 18178090
[TBL] [Abstract][Full Text] [Related]
16. 18F-Labeled FAUC 346 and BP 897 derivatives as subtype-selective potential PET radioligands for the dopamine D3 receptor.
Hocke C; Prante O; Salama I; Hübner H; Löber S; Kuwert T; Gmeiner P
ChemMedChem; 2008 May; 3(5):788-93. PubMed ID: 18306190
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of fluorine-substituted 1H-pyrrolo[2,3-b]pyridine derivatives for dopamine D4 receptor imaging.
Oh SJ; Lee KC; Lee SY; Ryu EK; Saji H; Choe YS; Chi DY; Kim SE; Lee J; Kim BT
Bioorg Med Chem; 2004 Nov; 12(21):5505-13. PubMed ID: 15465327
[TBL] [Abstract][Full Text] [Related]
18. New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.
Micheli F; Bonanomi G; Braggio S; Capelli AM; Celestini P; Damiani F; Di Fabio R; Donati D; Gagliardi S; Gentile G; Hamprecht D; Petrone M; Radaelli S; Tedesco G; Terreni S; Worby A; Heidbreder C
Bioorg Med Chem Lett; 2008 Feb; 18(3):901-7. PubMed ID: 18248991
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: 1H-pyrimidin-2-one derivatives.
Geneste H; Backfisch G; Braje W; Delzer J; Haupt A; Hutchins CW; King LL; Kling A; Teschendorf HJ; Unger L; Wernet W
Bioorg Med Chem Lett; 2006 Feb; 16(3):490-4. PubMed ID: 16290141
[TBL] [Abstract][Full Text] [Related]
20. Design of novel hexahydropyrazinoquinolines as potent and selective dopamine D3 receptor ligands with improved solubility.
Chen J; Ding K; Levant B; Wang S
Bioorg Med Chem Lett; 2006 Jan; 16(2):443-6. PubMed ID: 16290142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
